H.C. Wainwright lowered the firm’s price target on Cara Therapeutics to $7 from $15 and keeps a Buy rating on the shares. The IV Korsuva partner launch has disappointed, but the shares and sentiment do not reflect Cara’s oral DFK value and near-term catalysts, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CARA: